Predicting Chemotherapy Benefit across Different Races in Early-Stage Breast Cancer Patients Using the Oncotype DX Score.
Vikram R ShawChristopher Ian AmosChao ChengPublished in: Cancers (2023)
Our study provides a method for calibrating multigene molecular tests to help guide treatment decisions in racially and ethnically diverse patients with cancer. Specifically, we identify key chemotherapy sensitivity thresholds for the Oncotype DX recurrence score test in breast cancer patients and provide evidence that certain patients may benefit from receiving chemotherapy at a lower threshold than the current clinical guidelines suggest.
Keyphrases
- early stage
- locally advanced
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- chemotherapy induced
- clinical practice
- rectal cancer
- radiation therapy
- neoadjuvant chemotherapy
- patient reported outcomes
- free survival
- combination therapy
- patient reported
- smoking cessation